Rabeprazole Sodium Tablet, Delayed Release
Product Images NDC 70518-2590

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Rabeprazole Sodium (NDC 70518-2590). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Remedyrepack Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Rabeprazole Sodium 20mg 70518 2590 01

The label is for Rabeprazole Sodium 20 mg delayed-release tablets, packaged in a quantity of 30. It is repackaged by RemedyRepack Inc. The label indicates oral route and prescription use only. Additional details include the NDC number 70518-2590-01 and manufacturer information for Ascend Labs, LLC, Montvale, NJ.*

FDA Label Image

Rabeprazole Sodium 20mg 70518 2590 02

Label for Rabeprazole Sodium 20 mg delayed-release oral tablets. The package contains 60 tablets. Manufactured by Ascend Labs, LLC, Montvale, NJ, and repackaged by RemedyRepack Inc., Indiana, PA. Includes storage instructions and directions to see package insert for use.*

FDA Label Image

Rabeprazole Sodium 20mg 70518 2590 03

Label for Rabeprazole Sodium 20 mg delayed-release oral tablets. The label indicates a quantity of 30 tablets and notes that the product is repackaged by RemedyRepack Inc. Directions advise referring to the package insert. The label includes manufacturer information for Ascend Labs, LLC in Montvale, NJ, and storage temperature guidelines.*

FDA Label Image

Rabe-str (Rabe Str)

Chemical structure of rabeprazole sodium, showing its characteristic fused ring system and functional groups as illustrated in the figure.*

FDA Label Image

Rabe-str2 (Rabe Str2)

A line graph depicting mean heartburn scores over a study period of 28 days. The x-axis shows study days from -14 to 28, and the y-axis displays mean heartburn scores from 0 (None) to 4 (Very Severe). Three lines represent placebo and Rabeprazole Sodium doses of 10 mg and 20 mg, showing trends in heartburn severity across the groups.*

FDA Label Image

Rabe-str3 (Rabe Str3)

A line graph depicting heartburn scores over a 28-day study period comparing placebo and Rabeprazole Sodium 20 mg groups. The x-axis represents study days from -14 to 28, and the y-axis shows mean heartburn scores from 0 (none) to 4 (very severe). The graph includes two lines: a dashed line for placebo and a solid line for Rabeprazole Sodium 20 mg, indicating changes in heartburn severity over time.*

FDA Label Image

Rabe-str4 (Rabe Str4)

A line graph comparing mean heartburn scores over 28 study days between a placebo group (n=58) and a Rabeprazole Sodium 20 mg group (n=59). The x-axis shows study days from -14 to 28, and the y-axis depicts mean ANSI heartburn scores ranging from 0 (None) to 4 (Very Severe). The graph shows a notable reduction in heartburn scores starting at day 0 for both groups, with lower scores maintained in the Rabeprazole 20 mg group throughout the study.*

FDA Label Image

Remedy_label (Remedy Label)

Label for Rabeprazole Sodium 20 mg delayed-release tablets, quantity 60. The label includes manufacturer information for Ascend Labs, LLC, Montvale, NJ, and states repackaging by RemedyRepack Inc. It provides storage instructions and cautions to keep the medication out of reach of children. NDC 70518-2590-00 is displayed along with a QR code.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.